Teclistamab
Recommended OncologyAuthority RequiredLater-line line
Treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
1
Submissions
2026–26
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Mar 2026 Recommended Relapsed or refractory multiple myeloma (RRMM)
Access path
- Mar 2026Recommended · restricted
vs elranatamab
- PBS listing · Authority Required
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis versus elranatamab; no ICER calculated by design.
Decision context
PopulationAdult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy (including proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody), with WHO performance status ≤2, and no prior BCMA-directed therapy.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2026 | Recommended · restricted | elranatamab | — | Single-arm · ORR |